Liminatus Pharma, Inc. (LIMN)

The immediate outlook is severely clouded by a Nasdaq delisting notice triggered by non-compliance with market value requirements, a critical red flag that suggests the stock may soon trade over-the-counter with limited liquidity and heightened risk. While the company recently raised capital via a public offering and warrant exercise, these actions are likely defensive maneuvers to stave off delisting rather than signs of sustainable growth. Fundamentally, the business is in distress: the book value is negative, operating cash flow is massively negative, and the trailing EPS is deeply in the red. There is no dividend to provide income, and the price history shows a catastrophic collapse from a high of $33.66 to current levels around $0.14, indicating a complete loss of market confidence in the asset's viability. The statistical forecast models predict further downside, though their reliability is low given the extreme volatility and lack of data; however, this aligns with the fundamental reality of a failing biotech firm. Investors should view this as a speculative gamble on a turnaround that faces significant regulatory and financial headwinds, rather than a viable investment opportunity.